339 related articles for article (PubMed ID: 29070667)
1. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
Risacher SL; Anderson WH; Charil A; Castelluccio PF; Shcherbinin S; Saykin AJ; Schwarz AJ;
Neurology; 2017 Nov; 89(21):2176-2186. PubMed ID: 29070667
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
3. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal change of biomarkers in cognitive decline.
Lo RY; Hubbard AE; Shaw LM; Trojanowski JQ; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
Arch Neurol; 2011 Oct; 68(10):1257-66. PubMed ID: 21670386
[TBL] [Abstract][Full Text] [Related]
5. Baseline [
Teng E; Manser PT; Sanabria Bohorquez S; Wildsmith KR; Pickthorn K; Baker SL; Ward M; Kerchner GA; Weimer RM
Alzheimers Res Ther; 2021 Dec; 13(1):196. PubMed ID: 34852837
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.
Carmichael O; Schwarz C; Drucker D; Fletcher E; Harvey D; Beckett L; Jack CR; Weiner M; DeCarli C;
Arch Neurol; 2010 Nov; 67(11):1370-8. PubMed ID: 21060014
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
10. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
12. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
Hohman TJ; Bell SP; Jefferson AL;
JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
[TBL] [Abstract][Full Text] [Related]
13. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in the association between AD biomarkers and cognitive decline.
Koran MEI; Wagener M; Hohman TJ;
Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
[TBL] [Abstract][Full Text] [Related]
15. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
17. Quantitative susceptibility mapping demonstrates different patterns of iron overload in subtypes of early-onset Alzheimer's disease.
Kuchcinski G; Patin L; Lopes R; Leroy M; Delbeuck X; Rollin-Sillaire A; Lebouvier T; Wang Y; Spincemaille P; Tourdias T; Hacein-Bey L; Devos D; Pasquier F; Leclerc X; Pruvo JP; Verclytte S
Eur Radiol; 2023 Jan; 33(1):184-195. PubMed ID: 35881183
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.
Fjell AM; Walhovd KB; Fennema-Notestine C; McEvoy LK; Hagler DJ; Holland D; Brewer JB; Dale AM;
J Neurosci; 2010 Feb; 30(6):2088-101. PubMed ID: 20147537
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study.
Whitwell JL; Dickson DW; Murray ME; Weigand SD; Tosakulwong N; Senjem ML; Knopman DS; Boeve BF; Parisi JE; Petersen RC; Jack CR; Josephs KA
Lancet Neurol; 2012 Oct; 11(10):868-77. PubMed ID: 22951070
[TBL] [Abstract][Full Text] [Related]
20. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
